{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:07:37Z","timestamp":1794244057422,"version":"4.9.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Pharmacogenomics (PGx) is a scientific field that aims to understand how an individual\u2019s genetic code regulates drug metabolism and response. The response to many anesthetic drugs varies widely among patients due to many factors including, but not limited to, age, gender, and comorbidities. However, PGx contributes to this variability, particularly regarding adverse drug reactions. This review explores the influence of PGx on five commonly used induction agents in anesthesia: propofol, midazolam, ketamine, etomidate, and thiopental. Propofol metabolism is significantly affected by polymorphisms in CYP2B6, CYP2C9, and UGT1A9, influencing both efficacy and toxicity. Midazolam\u2019s PGx is mainly mediated by variations in CYP3A4, CYP3A5, and UDP-glucuronosyltransferase enzymes, with implications for sedation depth and drug clearance. Ketamine response is modulated by polymorphisms in metabolic enzymes (e.g. CYP2B6), as well as neurobiological targets such as brain-derived neurotrophic factor and gamma-aminobutyric acid (GABA) receptors, particularly in psychiatric applications. Etomidate shows less studied but emerging PGx associations, including single-nucleotide polymorphisms in GABA receptor subunits and metabolic enzymes, which may affect both sedative depth and cardiovascular stability. Thiopental is a rapid-acting metabolite whose effect stems from GABA-A receptor potentiation; no studies have yet identified specific genetic polymorphisms influencing its action. Overall, PGx provides a promising avenue for tailoring anesthetic management to improve patient safety and outcomes. However, clinical integration remains limited due to practical and infrastructural barriers. This review highlights the potential and current limitations of pharmacogenomic-guided anesthesia, underscoring its relevance in the era of precision medicine.<\/jats:p>","DOI":"10.1097\/fpc.0000000000000582","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T07:00:18Z","timestamp":1766559618000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenomics of commonly used intravenous anesthetics"],"prefix":"10.1097","volume":"36","author":[{"given":"Nayla","family":"Kassab","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Abourjeili","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Joe","family":"Eid","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Raphael","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"R1-20260128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/2045-9912.254641","article-title":"Pharmacogenomics of inhalational anesthetic agents.","volume":"9","author":"Nair","year":"2019","journal-title":"Med Gas Res"},{"key":"R2-20260128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/pme-2019-0056","article-title":"Challenges in anesthesia personalization: resolving the pharmacogenomic puzzle.","volume":"16","author":"Bach-Rojecky","year":"2019","journal-title":"Per Med"},{"key":"R4-20260128","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1213\/XAA.0000000000000397","article-title":"A case of delayed emergence after propofol anesthesia: genetic analysis.","volume":"7","author":"Yonekura","year":"2016","journal-title":"A A Case Rep"},{"key":"R5-20260128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4097\/kja.22654","article-title":"Mechanisms and implications in gene polymorphism mediated diverse reponses to sedatives, analgesics and muscle relaxants.","volume":"76","author":"Sun","year":"2023","journal-title":"Korean J Anesthesiol"},{"key":"R6-20260128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41397-021-00263-3","article-title":"A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4\u2009\u00b5g\u2009mL-1 at the time of loss of consciousness.","volume":"22","author":"Zheng","year":"2022","journal-title":"Pharmacogenomics J"},{"key":"R7-20260128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1742-7843.2008.00247.x","article-title":"Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9).","volume":"103","author":"Takahashi","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R8-20260128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bcpt.12277","article-title":"Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment.","volume":"115","author":"Khan","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R9-20260128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bja.2025.05.036","article-title":"Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review.","volume":"135","author":"Gerstman","year":"2025","journal-title":"Br J Anaesth"},{"key":"R10-20260128","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4103\/joacp.joacp_64_23","article-title":"Target-controlled infusion - Past, present, and future.","volume":"40","author":"Bidkar","year":"2024","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"R11-20260128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.phrs.2011.01.013","article-title":"NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes.","volume":"63","author":"Surapureddi","year":"2011","journal-title":"Pharmacol Res"},{"key":"R12-20260128","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.2174\/1389200224666230130110350","article-title":"Effects of CYP2B6Genetic variants on the propofol dose and response among jordanian arabic patients undergoing general anesthesia.","volume":"23","author":"Alrabayah","year":"2023","journal-title":"Curr Drug Metab"},{"key":"R13-20260128","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1212\/WNL.0b013e3182a1aa78","article-title":"Propofol-related infusion syndrome heralding a mitochondrial disease: case report.","volume":"81","author":"Savard","year":"2013","journal-title":"Neurology"},{"key":"R14-20260128","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cns.12099","article-title":"Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).","volume":"19","author":"Mion","year":"2013","journal-title":"CNS Neurosci Ther"},{"key":"R15-20260128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpsychires.2021.11.036","article-title":"Pharmacogenomics of ketamine: a systematic review.","volume":"145","author":"Meshkat","year":"2022","journal-title":"J Psychiatr Res"},{"key":"R16-20260128","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/ALN.0000000000001392","article-title":"Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance.","volume":"125","author":"Rao","year":"2016","journal-title":"Anesthesiology"},{"key":"R17-20260128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/NNR.0000000000000197","article-title":"Pharmacogenetics of ketamine-induced emergence phenomena: a pilot study.","volume":"66","author":"Aroke","year":"2017","journal-title":"Nurs Res"},{"key":"R19-20260128","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00000542-200310000-00022","article-title":"Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate.","volume":"99","author":"Paris","year":"2003","journal-title":"Anesthesiology"},{"key":"R20-20260128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/bja\/81.2.249","article-title":"Aging decreases the sensitivity of the GABA carrier to propofol and etomidate.","volume":"81","author":"Keita","year":"1998","journal-title":"Br J Anaesth"},{"key":"R21-20260128","doi-asserted-by":"crossref","first-page":"999132","DOI":"10.3389\/fgene.2022.999132","article-title":"Polymorphisms of pharmacogenetic candidate genes affect etomidate anesthesia susceptibility.","volume":"13","author":"Ma","year":"2022","journal-title":"Front Genet"},{"issue":"Suppl 1","key":"R23-20260128","first-page":"S72","article-title":"Molecular targets underlying general anaesthesia.","volume":"147","author":"Franks","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R25-20260128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/14622416.6.8.849","article-title":"Pharmacogenetics and anesthesiologists.","volume":"6","author":"Galley","year":"2005","journal-title":"Pharmacogenomics"},{"key":"R26-20260128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000542-199003000-00003","article-title":"Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.","volume":"72","author":"Stanski","year":"1990","journal-title":"Anesthesiology"},{"key":"R27-20260128","article-title":"Midazolam: pharmacology, clinical applications, and safety considerations.","author":"Karunarathna","year":"2024","journal-title":"Uva Clinical Pharmacology"},{"key":"R28-20260128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/ph17040473","article-title":"Pharmacokinetics, pharmacodynamics, and side effects of midazolam: a review and case example.","volume":"17","author":"Peter","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R29-20260128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jcph.230","article-title":"CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.","volume":"54","author":"Seng","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R30-20260128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/jcpt.13388","article-title":"The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.","volume":"46","author":"Flores-P\u00e9rez","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R31-20260128","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1097\/CCM.0000000000003638","article-title":"Midazolam dose optimization in critically ill pediatric patients with acute respiratory failure: a population pharmacokinetic-pharmacogenomic study.","volume":"47","author":"Zuppa","year":"2019","journal-title":"Crit Care Med"},{"key":"R32-20260128","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/0300060515587580","article-title":"Polymorphism rs4263535 in GABRA1 intron 4 was related to deeper sedation by intravenous midazolam.","volume":"43","author":"Choi","year":"2015","journal-title":"J Int Med Res"},{"key":"R33-20260128","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3389\/fgene.2020.00944","article-title":"Inherited and acquired determinants of hepatic CYP3A activity in humans.","volume":"11","author":"Matthaei","year":"2020","journal-title":"Front Genet"},{"key":"R34-20260128","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1213\/ANE.0000000000005951","article-title":"Pilot findings of pharmacogenomics in perioperative care: initial results from the first phase of the impress trial.","volume":"135","author":"Truong","year":"2022","journal-title":"Anesth Analg"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:34:42Z","timestamp":1785854082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000582","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"2025-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}